Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19F MRI Tracking of CS-1000 Labeled Stem Cells in Breast Reconstruction
NCT02035085Phase 1Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Jun 2014
- Primary completion
- Jun 2022
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CellSense in breast cancer, sponsored by Johns Hopkins University. Primary endpoint: 19F MRI signal over time at 18 months. Planned start Jun 2014; status: withdrawn.
02
Drugs
CellSense
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02035085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035085.